Advertisement

Tumor Lysis Syndrome After Platinum-based Chemotherapy in Castration-resistant Prostate Cancer With a BRCA2 Mutation: A Case Report

Published:September 06, 2018DOI:https://doi.org/10.1016/j.clgc.2018.09.001
      Tumor lysis syndrome is a potentially fatal oncologic emergency, extremely rare in prostate cancer, with very few cases reported in the literature.

      Keywords

      To read this article in full you will need to make a payment

      References

        • Serling-Boyd N.
        • Quandt Z.
        • Allaudeen N.
        Spontaneous tumor lysis syndrome in a patient with metastatic prostate cancer.
        Mol Clin Oncol. 2017; 6: 589-592
        • Mirrakhimov A.E.
        • Ali A.M.
        • Khan M.
        • Barbaryan A.
        Tumor lysis syndrome in solid tumors: an up to date review of the literature.
        Rare Tumors. 2014; 6: 68-76
        • Wright J.L.
        • Lin D.W.
        • Dewan P.
        • Montgomery R.B.
        Tumor lysis syndrome in a patient with metastatic, androgen independent prostate cancer.
        Int J Urol. 2005; 12: 1012-1013
        • Sarno J.
        Prevention and management of tumor lysis syndrome in adults with malignancy.
        J Adv Pract Oncol. 2013; 4: 101-106
        • Bhardwaj S.
        • Varma S.
        Rare incidence of tumor lysis syndrome in metastatic prostate cancer following treatment with docetaxel.
        J Oncol Pharm Pract. 2018; 24: 153-155
        • Kaplan M.A.
        • Kucukoner M.
        • Alpagat G.
        • Isikdogan A.
        Tumor lysis syndrome during radiotherapy for prostate cancer with bone and bone marrow metastases without visceral metastasis.
        Ann Saudi Med. 2012; 32: 306-308
        • Ignaszewski M.
        • Kohlitz P.
        Treatment-naïve spontaneous tumor lysis syndrome in metastatic prostate adenocarcinoma: an unusual suspect.
        Am J Emerg Med. 2017; 35 (1384.e1-1384.e2)
        • Tanvetyanon T.
        • Choudhury A.M.
        Fatal acute tumor lysis syndrome, hepatic encephalopathy and flare phenomenon following combined androgen blockade.
        J Urol. 2004; 171: 1627
        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics, 2018.
        CA Cancer J Clin. 2018; 68: 7-30
        • Abida W.
        • Sawyers C.L.
        Targeting DNA repair in prostate cancer.
        J Clin Oncol. 2018; 36: 1017-1019
        • Pomerantz M.M.
        • Spisák S.
        • Jia L.
        • et al.
        The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer.
        Cancer. 2017; 123: 3532-3539
        • Mateo J.
        • Carreira S.
        • Sandhu S.
        • et al.
        DNA-repair defects and olaparib in metastatic prostate cancer.
        N Engl J Med. 2015; 373: 1697-1708
        • Beltran H.
        • Tomlins S.
        • Aparicio A.
        • et al.
        Aggressive variants of castration-resistant prostate cancer.
        Clin Cancer Res. 2014; 20: 2846-2850
        • Aparicio A.M.
        • Shen L.
        • Tapia E.L.N.
        • et al.
        Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers.
        Clin Cancer Res. 2016; 22: 1520-1530
        • Basch E.
        • Loblaw D.A.
        • Oliver T.K.
        • et al.
        Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline.
        J Clin Oncol. 2014; 32: 3436-3448
        • Mateo J.
        • Boysen G.
        • Barbieri C.E.
        • et al.
        DNA repair in prostate cancer: biology and clinical implications.
        Eur Urol. 2017; 71: 417-425
        • Levy-Lahad E.
        • Friedman E.
        Cancer risks among BRCA1 and BRCA2 mutation carriers.
        Br J Cancer. 2007; 96: 11-15
        • Castro E.
        • Goh C.
        • Olmos D.
        • et al.
        Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.
        J Clin Oncol. 2013; 31: 1748-1757
        • Humeniuk M.S.
        • Zhang T.
        • Armstrong A.J.
        Exploiting DNA damage without repair: the activity of platinum chemotherapy in BRCA-mutated prostate cancers.
        Cancer. 2017; 123: 3441-3444
        • Sternberg C.N.
        • Petrylak D.P.
        • Sartor O.
        • et al.
        Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.
        J Clin Oncol. 2009; 27: 5431-5438
        • Aparicio A.M.
        • Harzstark A.L.
        • Corn P.G.
        • et al.
        Platinum-based chemotherapy for variant castrate-resistant prostate cancer.
        Clin Cancer Res. 2013; 19: 3621-3630
        • Aparicio A.
        • Xiao L.
        • Tapia E.L.N.
        • et al.
        The aggressive variant prostate carcinoma (AVPC) molecular signature (-MS) and platinum-sensitivity in castration resistant prostate cancer (CRPC).
        J Clin Oncol. 2017; 35: 5013
        • Beltran H.
        • Eng K.
        • Mosquera J.M.
        • et al.
        Whole-exome sequencing of metastatic cancer and biomarkers of treatment response.
        JAMA Oncol. 2015; 1: 466
      1. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Feb 29, 2000: Identifier NCT02598895: Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway, Nov 6, 2015.
        (Available at:)
        • Mazzoni S.
        Tumor lysis syndrome in anti-androgen-treated metastatic prostate cancer.
        Int Urol Nephrol. 2016; 48: 1837-1838
        • Lin C.-J.
        • Hsieh R.-K.
        • Lim K.-H.
        • Chen H.-H.
        • Cheng Y.-C.
        • Wu C.-J.
        Fatal spontaneous tumor lysis syndrome in a patient with metastatic, androgen-independent prostate cancer.
        South Med J. 2007; 100: 916-917
        • Sorscher S.
        Tumor lysis syndrome following docetaxel therapy for extensive metastatic prostate cancer.
        Cancer Chemother Pharmacol. 2004; 54: 191-192